# The Efficacy and Safety of Endostar Combined With Taxane-based Regimens for HER-2-negative MBC Patients

> **NCT02865304** · PHASE3 · UNKNOWN · sponsor: **Fujian Cancer Hospital** · enrollment: 80 (estimated)

## Conditions studied

- Angiogenesis
- Breast Cancer

## Interventions

- **DRUG:** endostar

## Key facts

- **NCT ID:** NCT02865304
- **Lead sponsor:** Fujian Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-12
- **Primary completion:** 2017-12
- **Final completion:** 2018-12
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2016-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02865304

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02865304, "The Efficacy and Safety of Endostar Combined With Taxane-based Regimens for HER-2-negative MBC Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02865304. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*